Dariusz Kotlęga Selected Research

Atrial Fibrillation

3/2019	Beneficial effects of pre-stroke statins use in cardioembolic stroke patients with atrial fibrillation: a hospital-based retrospective analysis.
1/2014	Atrial fibrillation and stroke - Coexistence and attitude to preventive therapy on the basis of Szczecin and Szczecin region patients.
3/2012	[Pathogenetic justification of statin use in ischaemic stroke prevention according to inflammatory theory in development of atherosclerosis].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dariusz Kotlęga Research Topics

Disease

16	Stroke (Strokes) 12/2022 - 01/2014
13	Ischemic Stroke 05/2022 - 03/2012
5	Atherosclerosis 04/2021 - 03/2012
4	Inflammation (Inflammations) 12/2022 - 01/2020
3	Atrial Fibrillation 03/2019 - 03/2012
2	Cognitive Dysfunction 10/2021 - 01/2021
1	Overactive Urinary Bladder (Overactive Bladder) 12/2023
1	Sleep Apnea Syndromes (Sleep Apnea) 09/2022
1	Obstructive Sleep Apnea 09/2022
1	Vascular Diseases (Vascular Disease) 10/2021
1	Neuroinflammatory Diseases 10/2021
1	Brain Edema (Cerebral Edema) 04/2021
1	Dementia (Dementias) 01/2021
1	Myocardial Infarction 10/2020
1	Embolic Stroke 03/2019
1	Coronary Disease (Coronary Heart Disease) 05/2016
1	Fatigue 01/2016
1	Atherosclerotic Plaque (Atheroma) 01/2015
1	Hemorrhagic Stroke 01/2015
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2015
1	Cerebral Hemorrhage 01/2015
1	Hypertension (High Blood Pressure) 01/2014
1	Dyslipidemias (Dyslipidemia) 01/2014
1	Type 2 Diabetes Mellitus (MODY) 01/2014

Drug/Important Bio-Agent (IBA)

4	Arachidonic Acid (Vitamin F)IBA 12/2022 - 01/2020
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2019 - 03/2012
3	LipidsIBA 12/2022 - 01/2014
3	Nonesterified Fatty Acids (NEFA)IBA 09/2022 - 01/2021
2	Linoleic Acid (Linoleate)IBA 12/2022 - 09/2022
2	Fatty Acids (Saturated Fatty Acids)IBA 09/2022 - 01/2021
2	ThromboxanesIBA 05/2022 - 10/2021
2	EicosanoidsIBA 10/2021 - 01/2020
2	LipoxinsIBA 04/2021 - 01/2020
2	Eicosapentaenoic AcidIBA 01/2021 - 10/2020
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2020 - 01/2018
2	C-Reactive ProteinIBA 04/2014 - 01/2014
1	Botulinum Toxins (Botulinum Toxin)IBA 12/2023
1	A-factor (Streptomyces)IBA 12/2022
1	AcidsIBA 09/2022
1	Thromboxane B2IBA 10/2021
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 10/2021
1	Biomarkers (Surrogate Marker)IBA 10/2021
1	9-hydroxyoctadecadienoic acidIBA 10/2021
1	N 30IBA 10/2021
1	resolvin D1IBA 10/2021
1	Dinoprostone (PGE2)FDA Link 10/2021
1	lipoxin A4IBA 04/2021
1	methyl ester 5(S),6(R)-7-trihydroxyheptanoic acidIBA 04/2021
1	Omega-6 Fatty Acids (Omega 6 Fatty Acids)IBA 04/2021
1	tricosanoic acidIBA 01/2021
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2021
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2021
1	alpha-Linolenic Acid (Linolenic Acid)IBA 01/2021
1	stearidonic acidIBA 01/2021
1	CytokinesIBA 10/2020
1	resolvin D2IBA 10/2020
1	Docosahexaenoic AcidsIBA 10/2020
1	Palmitic Acid (Hexadecanoic Acid)IBA 01/2020
1	Valine (L-Valine)FDA Link 05/2017
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 05/2017
1	Methionine (L-Methionine)FDA Link 05/2017
1	Proteins (Proteins, Gene)FDA Link 05/2017
1	Levodopa (L Dopa)FDA LinkGeneric 01/2016
1	HDL CholesterolIBA 01/2015
1	AntibodiesIBA 01/2014
1	Anti-Idiotypic AntibodiesIBA 01/2014
1	oxidized low density lipoproteinIBA 01/2014
1	Oxidoreductases (Dehydrogenase)IBA 03/2012

Therapy/Procedure

4	Therapeutics 10/2021 - 01/2014
2	Secondary Prevention 05/2016 - 03/2012
1	Transcranial Magnetic Stimulation 05/2017
1	Stroke Rehabilitation 05/2017